BriaCell Therapeutics Corp - BCTXF

BriaCell Therapeutics Corp., an immuno-oncology focused biotechnology company, engages in developing an approach to the management of cancer. The company is currently conducting a Phase I/IIa clinical trial for its lead product candidate, Bria-IMT, in patients with advanced breast cancer. The trial is being conducted along with the co-development of BriaDX, a companion diagnostic test. It is also conducting a roll-over combination study of Bria-IMT with pembrolizumab or ipilimumab for patients previously treated with Bria-IMT in its ongoing Phase I/IIa clinical trial in advanced breast cancer. In addition, the company is developing Bria-OTS, an off-the-shelf personalized immunotherapy for advanced stage breast cancer; and protein kinase C delta inhibitor, a novel therapeutic technology platform for the treatment of breast, pancreatic, and non-small cell lung cancer, as well as neuroendocrine tumors. BriaCell Therapeutics Corp. is headquartered in West Vancouver, Canada.